deltatrials
Active Not Recruiting INTERVENTIONAL NCT03155997

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE)

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Sponsor: Eli Lilly and Company

Conditions Breast Cancer
Interventions Abemaciclib Standard Adjuvant Endocrine Therapy
Updated 56 times since 2017 Last updated: Apr 7, 2026 Started: Jul 12, 2017 Primary completion: Mar 16, 2020 Completion: May 1, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Breast Cancer and is currently ongoing. Eli Lilly and Company leads this study, which shows 56 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jun 2017 – ~Jul 2017 · 30 days · monthly snapshot~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~Oct 2017 · 2 months · monthly snapshot~Oct 2017 – ~Nov 2017 · 31 days · monthly snapshot~Nov 2017 – ~Dec 2017 · 30 days · monthly snapshot~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Feb 2018 · 31 days · monthly snapshot~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshot~Mar 2018 – ~Apr 2018 · 31 days · monthly snapshot~Apr 2018 – ~May 2018 · 30 days · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Oct 2018 · 2 months · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Oct 2020 · 4 months · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Feb 2022 · 9 months · monthly snapshot~Feb 2022 – ~Apr 2023 · 14 months · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Aug 2023 · 3 months · monthly snapshot~Aug 2023 – ~Apr 2024 · 8 months · monthly snapshot~Apr 2024 – ~May 2024 · 30 days · monthly snapshot~May 2024 – ~Jun 2024 · 31 days · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Jan 2025 · 3 months · monthly snapshot~Jan 2025 – ~Feb 2025 · 31 days · monthly snapshot~Feb 2025 – ~Apr 2025 · 59 days · monthly snapshot~Apr 2025 – ~May 2025 · 30 days · monthly snapshot~May 2025 – ~Sep 2025 · 4 months · monthly snapshot~Sep 2025 – ~Apr 2026 · 8 months · monthly snapshotApr 28, 2026 – present · 3 months · daily API

Change History

56 versions recorded

  1. Apr 28, 2026 — Present [daily]

    Active Not Recruiting

    Phase: PHASE3 → None

  2. Sep 2025 — Apr 2026 [monthly]

    Active Not Recruiting PHASE3

  3. May 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE3

  4. Apr 2025 — May 2025 [monthly]

    Active Not Recruiting PHASE3

  5. Feb 2025 — Apr 2025 [monthly]

    Active Not Recruiting PHASE3

▶ Show 51 earlier versions

  1. Jan 2025 — Feb 2025 [monthly]

    Active Not Recruiting PHASE3

  2. Oct 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE3

  3. Sep 2024 — Oct 2024 [monthly]

    Active Not Recruiting PHASE3

  4. Aug 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

  5. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting PHASE3

  6. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

  7. May 2024 — Jun 2024 [monthly]

    Active Not Recruiting PHASE3

  8. Apr 2024 — May 2024 [monthly]

    Active Not Recruiting PHASE3

  9. Aug 2023 — Apr 2024 [monthly]

    Active Not Recruiting PHASE3

  10. May 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE3

  11. Apr 2023 — May 2023 [monthly]

    Active Not Recruiting PHASE3

  12. Feb 2022 — Apr 2023 [monthly]

    Active Not Recruiting PHASE3

  13. May 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE3

  14. Jan 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE3

  15. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  16. Nov 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE3

  17. Oct 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE3

  18. Jun 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE3

  19. May 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE3

  20. Apr 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE3

  21. Mar 2020 — Apr 2020 [monthly]

    Active Not Recruiting PHASE3

  22. Feb 2020 — Mar 2020 [monthly]

    Active Not Recruiting PHASE3

  23. Jan 2020 — Feb 2020 [monthly]

    Active Not Recruiting PHASE3

  24. Dec 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE3

  25. Nov 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE3

  26. Oct 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE3

  27. Sep 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE3

  28. Aug 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE3

  29. Jul 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE3

  30. Jun 2019 — Jul 2019 [monthly]

    Active Not Recruiting PHASE3

  31. May 2019 — Jun 2019 [monthly]

    Active Not Recruiting PHASE3

  32. Apr 2019 — May 2019 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  33. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE3

  34. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE3

  35. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE3

  36. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE3

  37. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE3

  38. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE3

  39. Aug 2018 — Oct 2018 [monthly]

    Recruiting PHASE3

  40. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE3

  41. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  42. Apr 2018 — May 2018 [monthly]

    Recruiting PHASE3

  43. Mar 2018 — Apr 2018 [monthly]

    Recruiting PHASE3

  44. Feb 2018 — Mar 2018 [monthly]

    Recruiting PHASE3

  45. Jan 2018 — Feb 2018 [monthly]

    Recruiting PHASE3

  46. Dec 2017 — Jan 2018 [monthly]

    Recruiting PHASE3

  47. Nov 2017 — Dec 2017 [monthly]

    Recruiting PHASE3

  48. Oct 2017 — Nov 2017 [monthly]

    Recruiting PHASE3

  49. Aug 2017 — Oct 2017 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  50. Jul 2017 — Aug 2017 [monthly]

    Not Yet Recruiting PHASE3

  51. Jun 2017 — Jul 2017 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer.

Contact Information

Sponsor contact:
  • Eli Lilly and Company
  • NSABP Foundation Inc
Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalborg, Denmark , Aarhus, Denmark , Abington, United States , Adana, Turkey (Türkiye) , Ahmedabad, India , Alcorcón, Spain , Amberg, Germany , Amsterdam, Netherlands , Anchorage, United States , Ankara, Turkey (Türkiye) and 609 more locations